Research & Development: Page 35
-
PharmaVoice Team/PharmaVoice
Patient Relationships: Physicians and Payers
Patients are taking an active role in developing relationships with all stakeholders within their healthcare environment. Over the past several years, the relationship between pharma companies and patients has garnered much of the industry’s attention. But as patients become more empowered, engag...
By Robin Robinson • March 1, 2020 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Real-World Evidence Comes of Age
Whether for product development, to support clinical trial designs, for regulatory compliance, or for commercial purposes, real-world data and real-world evidence are helping to transform pharmaceutical decision-making. The legal and regulatory environment is supportive of real-world data (RWD) a...
By PharmaVoice Team • March 1, 2020 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Ask the Experts: How Does Real World Evidence Ensure Market Access?
Our healthcare system has experienced a fundamental shift in stakeholders’ perceptions of product value and evidentiary thresholds to demonstrate comparative effectiveness, as well as a willingness by relevant decision makers to pay. This value-and-evidence-based landscape is now relying heavily ...
By Laura Clark • March 1, 2020 -
PharmaVoice Team/PharmaVoice
RWE is the Future of Clinical Research: Time to Get Onboard
We’ve been talking about the value of real-world evidence (RWE) for years. A myriad of new data sources is being developed and linked, and a core set of analytic tools are coming into use. We now see real-world data running the gamut from patient-generated data collected through wearables and soc...
By Nancy A. Dreyer • March 1, 2020 -
PharmaVoice Team/PharmaVoice
A Different Kind of Real-World Evidence: The Key Role That Patient-Provider Dialogue Research Can Play
All roads in healthcare lead to and from the medical visit. Well, maybe not all roads, but nearly all. The medical visit is central to the overarching healthcare structure and it is driven by the dialogue between patient and provider. The healthcare data and research landscape has been changing s...
By Katy Hewett • March 1, 2020 -
PharmaVoice Team/PharmaVoice
Clinical Educators Provide Support Along the Whole Patient Journey
Team Power The teams of clinical educators at VMS BioMarketing are driven to help patients on a one-to-one basis to manage chronic illnesses — in the field or on the phone each day. Taking A Step-Wise Approach to clinical education There is one club that no one wants to join, but for those who wo...
By Clinical Educator Teams • March 1, 2020 -
PharmaVoice Team/PharmaVoice
Executive Perspective: What Clinical technology Can Learn from Electronic Health Records
The future of clinical technology encompasses both better adoption of simple solutions and a slower evolution toward new technologies with the focus on the patient at the center. Mike Nolte CEO, Signant Health Early in the adoption of electronic health records (EHRs), some technology leaders reco...
By Mike Nolte • March 1, 2020 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
What’s old is new again This month’s cover story addresses an interesting take on science, or rather repurposing scientific R&D in a different way. For a whole host of reasons — patent cliffs, increasing discovery and development costs, mergers and acquisitions — companies are becoming more s...
By Taren Grom • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A Potential Cure for Hepatitis B Dr. Lawrence Blatt, CEO, Aligos Therapeutics, discusses his company’s research around antisense oligonucleotides as potential therapies for chronic hepatitis B and other diseases of the liver. Despite an available vaccine, the incidence of chronic hepatitis B (HBV...
By PharmaVoice Team • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
New Pipeline Pathways
The industry is becoming more strategic about repurposing its existing and shelved drugs. In the 1960s it became apparent that the drug thalidomide caused horrible birth defects in babies when pregnant mothers took it to treat their nausea. It was removed from the market. However today, that same...
By Robin Robinson • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Rare Disease: Rare But Not Scarce: The Struggle Faced By Millions
A single rare disease may afflict just a small number of people, but collectively up to 400 million people globally live with a rare disease. Exactly what is a rare disease? Collectively, rare isn’t scarce or infrequent. That’s the message that the organizers of Rare Disease Day 2020 are striving...
By PharmaVoice Team • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
Lessons Learned from rare Disease First Commercial Launches
There’s nothing more exciting, and more nerve-wracking, than a new product launch — even more so when it’s a company’s first commercial launch. We’ve had the privilege of working on more than 10 first commercial launches, most of them in rare disease. As an agency partner we’ve worked with biotec...
By Annemarie Armstrong • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
How the "Power of Why" Can Improve Adherence Rates in Rare Disease
Best-selling author and motivational speaker, Simon Sinek, is best known for his 2009 Ted Talk challenging organizations to set aside their list of product benefits and features to focus on the core purpose of their existence. He asks, WHY are you motivated to do what you do every day? Sinek sug...
By Kathi Hensen • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
Finding Patients With Rare Diseases — Two Truths and a Lie
The hope for many companies developing drugs for rare diseases is this: the significant unmet need, given a dearth of treatment options, will drive demand and thus product uptake. Unfortunately, the reality is more challenging. While we have seen a significant increase in the number of drugs for ...
By Susan Abedi • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
R&D INFLUENCER: Bert Hartog, Ph.D. — Janssen Pharmaceutical Companies of Johnson & Johnson
Unlocking clinical Bottlenecks We need to make more trials more accessible to more people. participate Bert Hartog, Ph.D., senior director at Janssen Clinical Innovation, Janssen Research & Development LLC is driven to eliminate the challenges preventing patients from participating in clinica...
By Bert Hartog • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
R&D INFLUENCER: Jill Johnston — WCG, Clinical Services Organization
Breaking Down the Roadblocks to Site Activation My focus is on getting life-saving drugs to patients as quickly as possible by reducing the time it takes sites to enroll patients into trials. There’s a big difference between people with a vision and those who can execute on that idea. Jill Johnst...
By Jill Johnston • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
Commanders & Chiefs: Innovators
Chief innovators provide their insights on what innovation means to them, keys to driving innovation, and what it takes to foster an innovation-driven company culture. Defining Innovation Garde. We define innovation as breaking business barriers through measurable and unique client-focused soluti...
By PharmaVoice Team • Feb. 1, 2020 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The Road Ahead As we head into 2020, closing out a decade punctuated by an ever-changing healthcare dynamic shaped by scientific discoveries, technological breakthroughs, innovation at every level, as well as global geopolitical forces, there is no doubt that the status quo is no longer a busines...
By Taren Grom • Jan. 1, 2020 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Fish Skin for Wounds Fertram Sigurjonsson, Founder and CEO of Kerecis, talks about his company’s skin-substitution technology, which comes from Icelandic cod. Fertram Sigurjonsson started Kerecis because he wanted to help people avoid life-altering amputations, which often result from hard-to-hea...
By Fertram Sigurjonsson • Jan. 1, 2020 -
PharmaVoice Team/PharmaVoice
Last Word
Creating an Innovative Culture Fabrice Chouraqui, former president of Novartis Pharmaceuticals US, discusses his vision for creating an organization that is fueled by innovation. PV: How do you define innovation and what was your vision for reshaping of the pharmaceutical division of Novartis in ...
By Fabrice Chouraqui • Jan. 1, 2020 -
PharmaVoice Team/PharmaVoice
Small Pharma Driving Big Pharma Innovation
The Path to R&D Innovation Lies in the Power of Small Pharma Visionary thought leaders such as Bernard Munos of InnoThink and the Milken Institute and Paul Stoffels, M.D., vice chairman of the executive committee and chief scientific officer, Johnson & Johnson, have been advocating for ye...
By Robin Robinson • Jan. 1, 2020 -
PharmaVoice Team/PharmaVoice
What Do Patients Want From Virtual Trials?
How to plan for a successful patient-centric virtual trial Virtual and hybrid clinical trials, which require few or no visits to a trial site, have arrived as part of the new frontier of innovative, patient-centric research models. Through telemedicine, online patient portals, and connected devic...
By Josh Rose • Jan. 1, 2020 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Imagining what’s next… By 2020, it’s estimated that 1.7 megabytes of data will be created every second for every person on earth; 90% of the world’s data has been created in the last two years; healthcare data is doubling every 18 months; 5 billion people around the world lack access to surgeons;...
By Taren Grom • Nov. 19, 2019 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
Novartis and Microsoft Collaborate on AI Lab Trend Watch: AI Partnerships and New Therapeutic Candidates Novartis has founded the Novartis AI innovation lab and is collaborating with Microsoft on the effort. The new lab aims to bolster Novartis AI capabilities from research through commercializat...
By PharmaVoice Team • Nov. 19, 2019 -
PharmaVoice Team/PharmaVoice
Last Word
Remaking Clinical Trials with the Patient in Mind Tammy Guld, Global Team Lead for Janssen Clinical Innovation, talks about how the clinical trial experience for patients can be improved. PV: How can pharma companies improve the clinical trial experience for patients and get medicines to market f...
By Tammy Guld • Nov. 19, 2019
Previous
